# Tenet Healthcare Corp: Form 10-Q for the period ended Jun 30, 2023

- Company: [Tenet Healthcare Corp](/companies/thc.md) (CIK 70318)
- Form: 10-Q
- Filed: 2023-07-31
- Accepted by EDGAR: Jul 31, 2023, 16:07 ET
- Period: 2023-06-30
- Accession: 0000070318-23-000041
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/70318/000007031823000041/thc-20230630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/70318/000007031823000041/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-04-01 to 2023-06-30 | $5.08bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2023-01-01 to 2023-06-30 | $10.10bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months, 2023-04-01 to 2023-06-30 | $604.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-01-01 to 2023-06-30 | $1.21bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-04-01 to 2023-06-30 | $226.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2023-01-01 to 2023-06-30 | $447.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-04-01 to 2023-06-30 | $80.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2023-01-01 to 2023-06-30 | $164.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | $293.0m | us-gaap:ProfitLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | $589.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2023-04-01 to 2023-06-30 | $1.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-01-01 to 2023-06-30 | $2.47 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-04-01 to 2023-06-30 | $1.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-01-01 to 2023-06-30 | $2.61 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-04-01 to 2023-06-30 | 104,778,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-01-01 to 2023-06-30 | 105,354,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | $1.05bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-04-01 to 2023-06-30 | $132.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Capital expenditure | 6 months, 2023-01-01 to 2023-06-30 | $367.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2023-01-01 to 2023-06-30 | $90.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-06-30 | $934.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-06-30 | $6.00bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-06-30 | $27.16bn | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $4.15bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-06-30 | $22.16bn | us-gaap:Liabilities |
| Shareholders' equity | at 2023-06-30 | $1.34bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 132,616 characters.

### INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to give context to the analysis of our financial information, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

- Management Overview
- Forward-Looking Statements
- Sources of Revenue for Our Hospital Operations Segment
- Results of Operations
- Liquidity and Capital Resources
- Critical Accounting Estimates

Our business consists of our Hospital Operations and other (“Hospital Operations”) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, a network of employed physicians and ancillary outpatient facilities. At June 30, 2023, our subsidiaries operated 61 hospitals serving primarily urban and suburban communities in nine states. Our Hospital Operations segment also included 107 outpatient facilities at June 30, 2023, including imaging centers, ancillary emergency facilities and micro‑hospitals.

Our Ambulatory Care segment, through our USPI Holding Company, Inc. subsidiary (“USPI”), held ownership interests in 455 ambulatory surgery centers (each, an “ASC”) (312 consolidated) and 24 surgical hospitals (eight consolidated) in 35 states at June 30, 2023. USPI’s facilities offer a range of procedures and service lines, including, among other specialties: orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; and urology. Effective June 30, 2022, we purchased all of the shares in USPI that Baylor University Medical Center (“Baylor”) held on that date for $406 million, which increased our ownership interest in USPI’s voting shares from 95% to 100%.

Our Conifer segment provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients through our Conifer Holdings, Inc. subsidiary (“Conifer”). At June 30, 2023, Conifer provided services to approximately 670 Tenet and non‑Tenet hospitals and other clients nationwide. Almost all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC, in which we own an interest of approximately 76%, or by one of its direct or indirect wholly owned subsidiaries.

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per adjusted admission and per adjusted patient day amounts). Continuing operations information includes, with respect to our Hospital Operations segment, the results of our same 60 hospitals operated throughout the six months ended June 30, 2023 and 2022, as well as the results of Piedmont Medical Center Fort Mill (“PMC Fort Mill Hospital”), the new acute care hospital we opened in South Carolina in September 2022. Continuing operations information excludes the results of our hospitals and other businesses classified as discontinued operations for accounting purposes. We believe this presentation is useful to investors because it includes the operations of all facilities in continuing operations for the entire time that we owned and operated them during the relevant period. In addition, continuing operations information reflects the impact of the addition or disposition of individual hospitals and other operations on our volumes, revenues and expenses. We present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable, and we present certain metrics on a per adjusted admission and per adjusted patient day basis to show trends other than volume.

In certain cases, information presented in MD&A for our Hospital Operations segment is described as presented on a same‑hospital basis, which includes the results of our same 60 hospitals operated throughout the six months ended June 30, 2023 and 2022, and excludes the results of our PMC Fort Mill Hospital, as well as our discontinued operations. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our current portfolio of hospitals and other operations that are comparable for the periods presented. Furthermore, same‑hospital data may more clearly reflect recent trends we are experiencing with respect to volumes, revenues and expenses exclusive of variations caused by the addition or disposition of individual hospitals and other operations.

The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non‑GAAP financial measures, including Adjusted EBITDA (as defined below), in this report and in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, we use these measures to define certain performance targets under our compensation programs.

“Adjusted EBITDA” is a non‑GAAP measure we define as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non‑operating income (expense), net, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition‑related costs, (11) depreciation and amortization, and (12) income (loss) from divested and closed businesses (i.e., health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.

We also present certain operational metrics and statistics in order to provide additional insight into our operational performance efficiency and to help investors better understand management’s view and strategic focus. We define these operational metrics and statistics as follows:

*Adjusted admissions—*represents actual admissions in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues;

*Adjusted patient days—*represents actual patient days in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient days by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues; and

*Utilization of licensed bed*s—represents patient days divided by the number of days in the period divided by average licensed beds.

### MANAGEMENT OVERVIEW

### OPERATING ENVIRONMENT AND TRENDS

*Ongoing Impact of the COVID-19 Pandemic—*The COVID‑19 pandemic continued to adversely impact various aspects of our operations during the six months ended June 30, 2023, although to a much lesser extent than previously experienced. We believe the strong patient volume growth in our Ambulatory Care and Hospital Operations segments so far this year are attributable in part to patient care deferred in prior years due to the pandemic. Regional changes in the prevalence of COVID‑19 infections and related patient acuity impact our patient volumes, service mix, revenue mix, operating expenses and net operating revenues. We have taken a number of actions over the past several years to increase our liquidity and mitigate the impact of fluctuations in our patient volumes and in our service and revenue mix.

Various federal legislative actions, including additional funding for the Public Health and Social Services Emergency Fund (collectively, the “COVID Acts”), during the public health emergency that began in January 2020 mitigated some of the adverse financial impacts of the COVID‑19 pandemic on our business. During the six months ended June 30, 2023 and June 30, 2022, we received cash payments from COVID‑19 relief programs totaling $7 million and $104 million, respectively. We recognized grant income of $8 million and $94 million during the three months ended June 30, 2023 and 2022, respectively, and $11 million and $100 million during the six months ended June 30, 2023 and 2022, respectively. The public health emergency for the COVID‑19 pandemic ended on May 11, 2023.

*Staffing and Labor Trends—*We compete with other healthcare providers in recruiting and retaining qualified personnel responsible for the operation of our facilities. There is limited availability of experienced medical support personnel nationwide, which drives up the wages and benefits required to recruit and retain employees. In particular, like others in the healthcare industry, we continue to experience a shortage of advanced practice providers and critical‑care nurses in certain disciplines and geographic areas. The COVID‑19 pandemic exacerbated this shortage as more employees chose to retire early, leave the workforce or take travel assignments.

Over the past several years, we have had to rely on higher-cost contract labor, which we compete with other healthcare providers to secure, and pay premiums above standard compensation for essential workers. We also depend on the available labor pool of semi‑skilled and unskilled workers in each of the areas where we operate. In some of our communities, employers across various industries have increased their minimum wage, which has created more competition and, in some cases, higher labor costs for this sector of employees. Although we continue to incur a higher level of contract labor expense than we have historically, our recruitment and retention efforts drove a reduction in this expense during the six months ended June 30, 2023.

*Inflation and Other General Economic Conditions—*Our business has been impacted by the rise in inflation and its effects on salaries, wages and benefits, as well as other costs. Additional economic factors, including unemployment rates and consumer spending, affect our patient volumes, service mix and revenue mix. Business closings and layoffs in the areas we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients to pay for services. Any significant deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations.

We have also experienced significant price increases in medical supplies, and we have encountered supply-chain disruptions, including shortages and delays, caused by current economic conditions. In addition, our Ambulatory Care segment has been impacted by shipment delays in construction materials and capital equipment with respect to its de novo facility development efforts, which are a key part of our portfolio expansion strategy.

*Industry Trends—*We believe that several key trends are continuing to shape the demand for healthcare services: (1) consumers, employers and insurers are actively seeking lower‑cost solutions and better value as they focus more on healthcare spending; (2) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (3) the growing aging population requires greater chronic disease management and higher‑acuity treatment; and (4) consolidation continues across the entire healthcare sector. Furthermore, the healthcare industry, in general, and the acute care hospital business, in particular, continue to be subject to significant regulatory uncertainty. Changes in federal or state healthcare laws, regulations, funding policies or reimbursement practices, especially those involving reductions to government payment rates, could have a significant impact on our future revenues and operations.

### STRATEGIES

*Expanding Our Ambulatory Care Segment—*We continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth, construction of new outpatient centers and strategic partnerships. We believe USPI’s ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in surgical techniques, medical technology and anesthesia, as well as the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase over time. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

During the years ended December 31, 2022 and 2021, we invested $264 million and $1.315 billion, respectively, to acquire ownership interests in new ASCs, increase our ownership interests in existing facilities and invest in de novo facilities. During the six months ended June 30, 2023, we acquired controlling ownership interests in 11 ASCs in which we did not have a previous investment, and we opened six de novo ASCs. We also continue to prioritize increasing our investment in our unconsolidated facilities. During the six months ended June 30, 2023, we acquired controlling ownership interests in four of our then‑unconsolidated ASCs, allowing us to consolidate their financial results.

*Driving Growth in Our Hospital Systems—*We remain committed to better positioning our hospital systems and competing more effectively in the ever‑evolving healthcare environment by focusing on driving performance through operational effectiveness, increasing capital efficiency and margins, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher‑demand and higher‑acuity clinical service lines (including outpatient lines), expanding patient and physician access, and optimizing our portfolio of assets. Over the past several years, we have undertaken enterprise‑wide cost‑efficiency measures, and we continue to transition certain support operations to our Global Business Center (“GBC”) in the Philippines. We incurred restructuring charges in conjunction with these initiatives in the six months ended June 30, 2023, and we could incur additional restructuring charges in the future.

We regularly review the marginal costs of providing certain services, and we use analytics to manage our operations and make staffing decisions. We also exit service lines, businesses and geographic areas that we believe are no longer a core part of our long‑term growth and synergy strategies. In January 2023, we entered into a definitive agreement to sell our 51% ownership interest in San Ramon Regional Medical Center and certain related operations to our joint venture partner. We expect the transaction to be completed in 2023, subject to regulatory review and customary closing conditions. We intend to further refine our portfolio of hospitals and other healthcare facilities when we believe such refinements will help us improve profitability, allocate capital more effectively in areas where we have a stronger presence, deploy proceeds on higher‑return investments across our business, enhance cash flow generation, reduce our debt and lower our ratio of debt‑to‑Adjusted EBITDA.

We also seek advantageous opportunities to grow our portfolio of hospitals and other healthcare facilities. In September 2022, we opened PMC Fort Mill Hospital, a new acute care hospital located in South Carolina. This 100-bed facility includes an emergency department, multi-specialty operating rooms, an intensive care unit, and labor and delivery rooms.

*Improving the Customer Care Experience—*As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: (1) establishing networks of physicians and facilities that provide convenient access to services across the care continuum; (2) expanding service lines aligned with growing community demand, including a focus on aging and chronic disease patients; (3) offering greater affordability and predictability, including simplified registration and discharge procedures, particularly in our outpatient centers; (4) improving our culture of service; and (5) creating health and benefit programs, patient education and health literacy materials that are customized to the needs of the communities we serve. Through these efforts, we intend to improve the customer care experience in every part of our operations.

*Driving Conifer’s Growth—*Conifer serves approximately 670 Tenet and non‑Tenet hospitals and other clients nationwide. In addition to providing revenue cycle management services to health systems and physicians, Conifer provides support to both providers and self‑insured employers seeking assistance with clinical integration, financial risk management and population health management. We believe that our success in growing Conifer and increasing its profitability depends in part on our success in executing the following strategies: (1) attracting hospitals and other healthcare providers that currently handle their revenue cycle management processes internally as new clients; (2) generating new client relationships through opportunities from USPI and Tenet’s acute care hospital acquisition and divestiture activities; (3) expanding revenue cycle management and value‑based care service offerings through organic development and small acquisitions; (4) leveraging data from tens of millions of patient interactions for continued enhancement of the value‑based care environment to drive competitive differentiation; and (5) maximizing opportunities through automation and offshoring to improve the effectiveness and efficiency of Conifer’s services.

*Improving Profitability—*We continue to focus on growing patient volumes and effective cost management as a means to improve profitability. Our inpatient admissions have been constrained in recent years by the COVID‑19 pandemic, increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co‑pays, co‑insurance amounts and deductibles, changing consumer behavior, and adverse economic conditions and demographic trends in certain areas where we operate. Our business has also been impacted by the rise in inflation and its effects on wages and costs. However, we also believe that emphasis on higher‑demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business, cultivation of our culture of service, participation in Medicare Advantage health plans that have been experiencing higher growth rates than traditional Medicare, and contracting strategies that create shared value with payers should help us grow our patient volumes over time. We are also continuing to pursue new opportunities to enhance efficiency, including further integration of enterprise‑wide centralized support functions, outsourcing additional functions unrelated to direct patient care, and reducing clinical and vendor contract variation.

*Reducing Our Leverage Over Time—*All of our long‑term debt has a fixed rate of interest, except for outstanding borrowings under our senior secured revolving credit facility (as amended to date, the “Credit Agreement”), of which we currently have none. In addition, the maturity dates of our notes are staggered from 2026 through 2031. We believe that our capital structure helps to minimize the near‑term impact of increased interest rates, and the staggered maturities of our debt allow us to retire or refinance our debt over time. It remains our long‑term objective to reduce our debt and lower our ratio of debt‑to‑Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk.

In May 2023, we issued $1.350 billion aggregate principal amount of 6.750% senior secured first lien notes, which will mature in May 2031 (the “2031 Senior Secured First Lien Notes”). We used the proceeds from this issuance, together with cash on hand, to finance the redemption of all $589 million aggregate principal amount then-outstanding of our 4.625% senior secured first lien notes due September 2024 (the “September 2024 Senior Secured First Lien Notes”) and all $756 million aggregate principal amount then-outstanding of our 4.625% senior secured first line notes due July 2024 (the “July 2024 Senior Secured First Lien Notes”) in May and June 2023, respectively.

*Repurchasing Stock—*In October 2022, our board of directors authorized the repurchase of up to $1 billion of our common stock through a share repurchase program. Repurchases will be made in accordance with applicable securities laws and may be made at management’s discretion from time to time in open-market or privately negotiated transactions, subject to market conditions and other factors. The share repurchase program does not obligate us to acquire any particular amount of common stock, and it may be suspended for periods or discontinued at any time before its scheduled expiration date of December 31, 2024. We paid approximately $90 million to repurchase a total of 1,485,983 shares during the six months ended June 30, 2023, or an average of $60.55 per share.

Our ability to execute on our strategies and respond to the aforementioned trends in the current operating environment is subject to numerous risks and uncertainties, all of which may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report on Form 10‑K for the year ended December 31, 2022 (our “Annual Report”).

### RECENT RESULTS OF OPERATIONS

The following table presents selected operating statistics for our Hospital Operations and Ambulatory Care segments on a continuing operations basis:

| Hospital Operations – hospitals and related outpatient facilities: | Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 61 | 60 | 1 | (1) |
| Total admissions | 132,754 | 128,068 | 3.7% |  |
| Adjusted admissions | 248,589 | 239,031 | 4.0% |  |
| Paying admissions (excludes charity and uninsured) | 126,861 | 121,722 | 4.2% |  |
| Charity and uninsured admissions | 5,893 | 6,346 | (7.1)% |  |
| Admissions through emergency department | 99,572 | 96,137 | 3.6% |  |
| Emergency department visits, outpatient | 545,990 | 541,096 | 0.9% |  |
| Total emergency department visits | 645,562 | 637,233 | 1.3% |  |
| Total surgeries | 87,846 | 87,387 | 0.5% |  |
| Patient days — total | 677,430 | 658,995 | 2.8% |  |
| Adjusted patient days | 1,215,610 | 1,192,999 | 1.9% |  |
| Average length of stay (days) | 5.10 | 5.15 | (1.0)% |  |
| Average licensed beds | 15,472 | 15,382 | 0.6% |  |
| Utilization of licensed beds | 48.1% | 47.1% | 1.0% | (1) |
| Total visits | 1,401,442 | 1,413,222 | (0.8)% |  |
| Paying visits (excludes charity and uninsured) | 1,328,839 | 1,331,959 | (0.2)% |  |
| Charity and uninsured visits | 72,603 | 81,263 | (10.7)% |  |
| **Ambulatory Care:** |  |  |  |  |
| Total consolidated facilities (at end of period) | 320 | 269 | 51 | (1) |
| Total consolidated cases | 346,402 | 317,437 | 9.1% |  |

(1) The change is the difference between the 2023 and 2022 amounts presented.

Total admissions increased by 4,686, or 3.7%, in the three months ended June 30, 2023 compared to the three months ended June 30, 2022, including an increase of admissions through our emergency departments of 3,435, or 3.6%. Total emergency department visits increased by 1.3% during the three‑month period in 2023 compared to the same period in 2022. The increase in our Ambulatory Care segment’s total consolidated cases of 9.1% in the three months ended June 30, 2023, as compared to the same period in 2022, was primarily attributable to incremental case volume from our recently acquired facilities and same‑facility case growth, partially offset by the impact of the closure and deconsolidation of certain facilities.

The following table presents net operating revenues by segment on a continuing operations basis:

| Revenues | Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Hospital Operations prior to inter-segment eliminations | $3,922 | $3,645 | 7.6% |
| Ambulatory Care | 942 | 771 | 22.2% |
| Conifer | 323 | 333 | (3.0)% |
| Inter-segment eliminations | (105) | (111) | (5.4)% |
| **Total** | **$5,082** | **$4,638** | **9.6%** |

Consolidated net operating revenues increased by $444 million, or 9.6%, in the three months ended June 30, 2023 compared to the same period in 2022. The increase of $277 million, or 7.6%, in our Hospital Operations segment’s net operating revenues prior to inter‑segment eliminations for the three‑month period in 2023 compared to the same period in 2022 was primarily due to the opening of our PMC Fort Mill Hospital in September 2022, higher patient volume, the adverse impacts associated with a cybersecurity incident in the 2022 period and negotiated commercial rate increases. Net operating revenues in our Ambulatory Care segment increased by $171 million, or 22.2%, in the three months ended June 30, 2023 compared to the same period in 2022. This change was primarily driven by our recently acquired ASCs, an increase in case volume and higher net revenue per case, partially offset by the impact of the closure and deconsolidation of certain facilities. Conifer’s revenues, net of inter‑segment eliminations, decreased by $4 million, or 1.8%, during the three months ended June 30, 2023 compared to the same period in 2022. During the three months ended June 30, 2023 and 2022, we recognized grant income of $8 million and $94 million, respectively, which amounts are not included in net operating revenues.

Our accounts receivable days outstanding (“AR Days”) from continuing operations were 56.4 days at June 30, 2023 and 58.3 days at December 31, 2022. Our AR Days target is less than 55 days. AR Days are calculated as our accounts receivable from continuing operations on the last date in the quarter divided by our net operating revenues from continuing operations for the quarter ended on that date divided by the number of days in the quarter. The AR Days calculation includes our Hospital Operations segment’s contract assets and excludes our California provider fee revenues.

The following table provides information about selected operating expenses by segment on a continuing operations basis:

| Hospital Operations: | Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,872 | $1,752 | 6.8% |
| Supplies | 636 | 605 | 5.1% |
| Other operating expenses | 930 | 840 | 10.7% |
| **Total** | **$3,438** | **$3,197** | **7.5%** |
| **Ambulatory Care:** |  |  |  |
| Salaries, wages and benefits | $240 | $201 | 19.4% |
| Supplies | 253 | 205 | 23.4% |
| Other operating expenses | 132 | 100 | 32.0% |
| **Total** | **$625** | **$506** | **23.5%** |
| **Conifer:** |  |  |  |
| Salaries, wages and benefits | $173 | $173 | —% |
| Supplies | 2 | 1 | 100.0% |
| Other operating expenses | 63 | 66 | (4.5)% |
| **Total** | **$238** | **$240** | **(0.8)%** |
| **Total:** |  |  |  |
| Salaries, wages and benefits | $2,285 | $2,126 | 7.5% |
| Supplies | 891 | 811 | 9.9% |
| Other operating expenses | 1,125 | 1,006 | 11.8% |
| **Total** | **$4,301** | **$3,943** | **9.1%** |
| **Rent/lease expense(1):** |  |  |  |
| Hospital Operations | $67 | $68 | (1.5)% |
| Ambulatory Care | 32 | 28 | 14.3% |
| Conifer | 4 | 3 | 33.3% |
| **Total** | **$103** | **$99** | **4.0%** |

(1) Included in other operating expenses.

The following table provides information about our Hospital Operations segment’s selected operating expenses per adjusted admission on a continuing operations basis:

| Hospital Operations: | Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Salaries, wages and benefits per adjusted admission | $7,528 | $7,331 | 2.7% |
| Supplies per adjusted admission | 2,564 | 2,534 | 1.2% |
| Other operating expenses per adjusted admission | 3,744 | 3,509 | 6.7% |
| **Total per adjusted admission** | **$13,836** | **$13,374** | **3.5%** |

Salaries, wages and benefits expense for our Hospital Operations segment increased by $120 million, or 6.8%, in the three months ended June 30, 2023 compared to the same period in 2022. This change was primarily attributable to merit increases for certain of our employees and increased employee benefits, recruiting and retention costs in the 2023 period, as well as higher incentive compensation expense. These factors were partially offset by a decrease in contract labor expense. On a per adjusted admission basis, salaries, wages and benefits expense increased by 2.7% in the three months ended June 30, 2023 compared to the three months ended June 30, 2022, primarily due to the factors described above.

Supplies expense for our Hospital Operations segment increased by $31 million, or 5.1%, during the three months ended June 30, 2023 compared to the three months ended June 30, 2022. This increase was driven by higher patient volume, as well as the impact of general market conditions and inflation. On a per adjusted admission basis, supplies expense increased by 1.2% in the three months ended June 30, 2023 compared to the three months ended June 30, 2022, reflecting our continued focus on cost‑efficiency measures.

Other operating expenses for our Hospital Operations segment increased by $90 million, or 10.7%, in the three months ended June 30, 2023 compared to the same period in 2022. This change was primarily attributable to higher malpractice expense and medical fees during the three months ended June 30, 2023. On a per adjusted admission basis, other operating expenses in the three months ended June 30, 2023 increased by 6.7% compared to the same period in 2022, primarily due to the factors described above.

### LIQUIDITY AND CAPITAL RESOURCES OVERVIEW

Cash and cash equivalents were $934 million at June 30, 2023 compared to $766 million at March 31, 2023. Significant cash flow items in the three months ended June 30, 2023 included:

- Net cash provided by operating activities before interest, taxes, discontinued operations, and restructuring charges, acquisition‑related costs, and litigation costs and settlements of $1.078 billion;
- Proceeds from the issuance of $1.350 billion aggregate principal amount of our 2031 Senior Secured First Lien Notes;
- Debt payments of $1.392 billion, including $1.352 billion to redeem $1.345 billion aggregate principal amount outstanding of our September 2024 Senior Secured First Lien Notes and July 2024 Senior Secured First Lien Notes;
- Interest payments of $268 million;
- Income tax payments of $158 million;
- $136 million of distributions paid to noncontrolling interests;
- Capital expenditures of $132 million;
- $48 million of payments for purchases of businesses or joint venture interests;
- $40 million of payments to repurchase a total of 579,637 shares of our common stock under the share repurchase program; and
- Payments of $38 million for the purchase of noncontrolling interests.

Net cash provided by operating activities was $1.047 billion in the six months ended June 30, 2023 compared to $347 million in the six months ended June 30, 2022. Key factors contributing to the change between the 2023 and 2022 periods included the following:

- No Medicare advances recouped or repaid in the six months ended June 30, 2023 compared to $475 million recouped or repaid during the same period in 2022;
- Higher interest payments of $29 million during the six months ended June 30, 2023 compared to the same period in 2022;
- Higher income tax payments of $18 million in the 2023 period; and
- The timing of other working capital items.

### FORWARD-LOOKING STATEMENTS

This report includes “forward‑looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward‑looking statements, including (but not limited to) disclosures regarding (1) the impact of the COVID-19 pandemic, (2) our future earnings, financial position, and operational and strategic initiatives, and (3) developments in the healthcare industry. Forward‑looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are indeterminate. They involve known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward‑looking statements. Such factors include, but are not limited to, the risks described in the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report.

When considering forward‑looking statements, you should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in these reports occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward‑looking statement. We specifically disclaim any obligation to update any information contained in a forward‑looking statement or any forward‑looking statement in its entirety except as required by law.

All forward‑looking statements attributable to us are expressly qualified in their entirety by this cautionary information.

### SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS SEGMENT

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity‑based health insurance companies and uninsured patients (that is, patients who do not have health insurance and are not covered by some other form of third‑party arrangement).

The following table presents the sources of net patient service revenues for our hospitals and related outpatient facilities, expressed as percentages of net patient service revenues from all sources:

| 2023 | Three Months Ended June 30, 2022 |  | Increase (Decrease)(1) 2023 | Six Months Ended June 30, 2022 |  | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Medicare | 16.6% | 17.3% | (0.7)% | 16.9% | 17.5% | (0.6)% |
| Medicaid | 7.3% | 8.0% | (0.7)% | 7.6% | 7.5% | 0.1% |
| Managed care(2) | 71.0% | 68.8% | 2.2% | 70.6% | 69.2% | 1.4% |
| Uninsured | 0.8% | 1.1% | (0.3)% | 0.8% | 1.1% | (0.3)% |
| Indemnity and other | 4.3% | 4.8% | (0.5)% | 4.1% | 4.7% | (0.6)% |

(1) The change is the difference between the 2023 and 2022 percentages presented.

(2) Includes Medicare and Medicaid managed care programs.

Revenues related to the Texas Comprehensive Hospital Increase Reimbursement Program (“CHIRP”) are presented in managed care net patient service revenues in the table above. Amounts we were assessed to support CHIRP following its approval in 2022 were presented in Medicaid revenues in prior periods, but have been reclassified to managed care revenues to conform to the current‑year presentation in the same payer group as the revenues to more clearly reflect the results of our participation in this program. Assessments to support CHIRP totaled $24 million and $20 million during the three months ended June 30, 2023 and 2022, respectively, and $50 million and $77 million during the six months ended June 30, 2023 and 2022, respectively.

Our payer mix on an admissions basis for our hospitals, expressed as a percentage of total admissions from all sources, is presented below:

| Admissions from: | Three Months Ended June 30, 2023 | 2022 | Increase (Decrease)(1) 2023 | Six Months Ended June 30, 2022 |  | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Medicare | 19.9% | 20.7% | (0.8)% | 20.3% | 21.1% | (0.8)% |
| Medicaid | 4.9% | 5.6% | (0.7)% | 4.9% | 5.6% | (0.7)% |
| Managed care(2) | 67.4% | 65.7% | 1.7% | 67.1% | 65.3% | 1.8% |
| Charity and uninsured | 4.4% | 5.0% | (0.6)% | 4.4% | 4.8% | (0.4)% |
| Indemnity and other | 3.4% | 3.0% | 0.4% | 3.3% | 3.2% | 0.1% |

(1) The change is the difference between the 2023 and 2022 percentages presented.

(2) Includes Medicare and Medicaid managed care programs.

### GOVERNMENT PROGRAMS

The Centers for Medicare & Medicaid Services (“CMS”) is an agency of the U.S. Department of Health and Human Services (“HHS”) that administers a number of government programs authorized by federal law; it is the single largest payer of healthcare services in the United States. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, as well as some younger people with certain disabilities and conditions, and is provided without regard to income or assets. Medicaid is co‑administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The Children’s Health Insurance Program (“CHIP”), which is also co‑administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. Funding for the CHIP has been reauthorized through federal fiscal year (“FFY”) 2029.

### Medicare

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee‑for‑service (“FFS”) payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private FFS Medicare special needs plans and Medicare medical savings account plans. Our total net patient service revenues from continuing operations of the hospitals and related outpatient facilities in our Hospital Operations segment for services provided to patients enrolled in the Original Medicare Plan were $599 million and $579 million for the three months ended June 30, 2023 and 2022, respectively, and $1.212 billion and $1.198 billion for the six months ended June 30, 2023 and 2022, respectively. A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.

### Medicaid

Medicaid programs and the corresponding reimbursement methodologies vary from state‑to‑state and from year‑to‑year. Estimated revenues under various state Medicaid programs, including state‑funded Medicaid managed care programs, constituted approximately 18.3% and 19.2% of the total net patient service revenues of our acute care hospitals and related outpatient facilities during the six months ended June 30, 2023 and 2022, respectively. We also receive disproportionate share hospital (“DSH”) and other supplemental revenues under various state Medicaid programs. Our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $190 million and $193 million for the three months ended June 30, 2023 and 2022, respectively, and $395 million and $369 million for the six months ended June 30, 2023 and 2022, respectively.

Even prior to the COVID‑19 pandemic, several states in which we operate faced budgetary challenges that resulted in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted supplemental payment programs authorized under the Social Security Act. Continuing pressure on state budgets and other factors, including legislative and regulatory changes, could result in future reductions to Medicaid payments, payment delays or changes to Medicaid supplemental payment programs. Federal government denials or delayed approvals of waiver applications or extension requests by the states where we operate could materially impact our Medicaid funding levels.

Total Medicaid and Medicaid managed care net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment were $640 million and $656 million for the three months ended June 30, 2023 and 2022, respectively, and $1.312 billion and $1.315 billion for the six months ended June 30, 2023 and 2022, respectively. During the six months ended June 30, 2023, Medicaid and Medicaid managed care revenues comprised 41% and 59%, respectively, of our Medicaid‑related net patient service revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations segment. All Medicaid and Medicaid managed care patient service revenues are presented net of provider taxes or assessments paid by our hospitals.

Because we cannot predict what actions the federal government or the states may take under existing or future legislation and/or regulatory changes to address budget gaps, deficits, Medicaid expansion, Medicaid eligibility redeterminations by the states, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation or regulatory action might have on our business; however, the impact on our future financial position, results of operations or cash flows could be material.

### Regulatory and Legislative Changes

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems, as well as other government programs impacting our business, are provided below.

*Proposed Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems—*Section 1886(d) of the Social Security Act requires CMS to update Medicare inpatient FFS payment rates for hospitals reimbursed under the inpatient prospective payment systems (“IPPS”) annually. The updates generally become effective October 1, the beginning of the FFY. In April 2023, CMS issued proposed changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2024 Rates (“Proposed IPPS Rule”). The Proposed IPPS Rule includes the following proposed payment and policy changes, among others:

- A market basket increase of 3.0% for Medicare severity‑adjusted diagnosis‑related group (“MS‑DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record technology; CMS also proposed a 0.2% multifactor productivity reduction required by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Affordable Care Act”), that results in a net operating payment update of 2.8% before budget neutrality adjustments;
- An increase in the cost outlier threshold from $38,859 to $40,732;
- A 4.5% net increase in the capital federal MS‑DRG rate;
- Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share hospital payments (“UC‑DSH Amounts”); and
- The inclusion of certain rural reclassified hospitals with geographically rural hospitals in the calculation of the rural wage index and the calculation of the wage index floor for urban hospitals in the same state.

According to CMS, the combined impact of the proposed payment and policy changes in the Proposed IPPS Rule for operating costs will yield an average 2.8% increase in Medicare operating MS‑DRG FFS payments for hospitals in urban areas and an average 2.8% increase in such payments for proprietary hospitals in FFY 2024. We estimate that all of the proposed payment and policy changes affecting operating MS‑DRG and UC‑DSH Amounts will result in a 3.7% increase in our annual Medicare FFS IPPS payments, which yields an estimated increase of approximately $59 million. Because of the uncertainty associated with various factors that may influence our future IPPS payments by individual hospital, including legislative, regulatory or legal actions, admission volumes, length of stay and case mix, as well as potential changes to the Proposed IPPS Rule, we cannot provide any assurances regarding our estimate of the impact of the proposed payment and policy changes.

The statutes and regulations that govern Medicare DSH payments have been the subject of various administrative appeals and lawsuits, and our hospitals have been participating in such appeals, including challenges to the inclusion of the Medicare Advantage (Part C) days used in the DSH calculation as set forth in the Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2005 Rates. In June 2023, CMS issued a Final Action on the Treatment of Medicare Part C Days in the Calculation of a Hospital’s Medicare Disproportionate Patient Percentage for discharges occurring prior to October 1, 2013. This action finalized CMS’ August 2020 proposed rule to include Medicare Advantage days in the Medicare fraction for all periods prior to October 1, 2013, and CMS expects no effect on payments as payments previously made already reflect this policy. We are not able to predict whether CMS’s final action will be the subject of further or new legal challenges nor are we able to predict the outcome of those challenges, if any.

*Proposed Payment and Policy Changes to the Medicare Outpatient Prospective Payment and Ambulatory Surgery Center Payment Systems—*In July 2023, CMS released proposed policy changes and payment rates for the Hospital Outpatient Prospective Payment System (“OPPS”) and Ambulatory Surgical Center Payment System for calendar year (“CY”) 2024 (“Proposed OPPS/ASC Rule”). The Proposed OPPS/ASC Rule includes the following proposed payment and policy changes:

- An estimated net increase of 2.8% for the OPPS rates based on an estimated market basket increase of 3.0%, reduced by a multifactor productivity adjustment required by the Affordable Care Act of 0.2%; and
- A 2.8% increase to the Ambulatory Surgical Center payment rates.

CMS projects that the combined impact of the proposed payment and policy changes in the Proposed OPPS/ASC Rule will yield an average 2.8% increase in Medicare FFS OPPS payments for hospitals in urban areas and an average 3.4% increase in Medicare FFS OPPS payments for proprietary hospitals. The projected annual impact of the payment and policy changes in the Proposed OPPS/ASC Rule is an increase to Medicare FFS outpatient revenues of approximately $23 million, or 4.2%, for our acute care hospitals and $17 million, or 2.6%, for USPI's ASCs and surgical hospitals. Because of the uncertainty associated with various factors that may influence our future OPPS payments, including legislative or legal actions, volumes and case mix, as well as potential changes to the proposed rule, we cannot provide any assurances regarding our estimate of the impact of the proposed payment and policy changes.

*Proposed Rule on the Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022—*CMS’ 340B program allows certain hospitals (i.e., only nonprofit organizations with specific federal designations and/or funding) (“340B Hospitals”) to purchase drugs at discounted rates from drug manufacturers (“340B Drugs”). In the CY 2018 final rule regarding OPPS payment and policy changes, CMS reduced the payment for 340B Drugs from the average sales price (“ASP”) plus 6% to the ASP minus 22.5% and made a corresponding budget-neutral increase to payments to all hospitals for other drugs and services reimbursed under the OPPS (the “340B Payment Adjustment”). CMS retained the same 340B Payment Adjustment in the final rules regarding OPPS payment and policy changes for CYs 2019 through 2022. Certain hospital associations and hospitals commenced litigation challenging CMS’ authority to impose the 340B Payment Adjustment for CYs 2018, 2019 and 2020. Following the initial court decisions and a series of appeals, the U.S. Supreme Court (the “Supreme Court”) unanimously ruled in June 2022 that the decision to impose the 340B Payment Adjustment in CYs 2018 and 2019 was unlawful, and the case was remanded to the lower courts to determine the appropriate remedy. In response to the Supreme Court’s decision, the final rules regarding OPPS payment and policy changes for CY 2023 affirmed that CMS was now applying the default rate, generally ASP plus 6%, to 340B Drugs and biologicals, and it had removed the 340B Payment Adjustment made in 2018. In January 2023, the U.S. District Court for the District of Columbia issued an opinion remanding the case to HHS to determine the remediation for the prior years’ underpayments. In response, CMS released the Prospective Payment System: Remedy for 340B-Acquired Drugs Purchased in Cost Years 2018-2022 Proposed Rule in July 2023. The proposed rule provides for a one-time lump sum remedy payment to each 340B Hospital that received a cut in 340B Drug payments from 2018 through 2022 (to which CMS will not apply interest). Due to budget neutrality requirements, CMS also proposed a reduction to future non-drug item and service payments through an adjustment to the OPPS conversion factor by minus 0.5% starting in CY 2025 until the full amount is offset (which CMS estimates will take 16 years). We estimate this adjustment will result in a reduction of less than $10 million annually to our acute care and surgical hospital revenue.

*Proposed Payment and Policy Changes to the Medicare Physician Fee Schedule—*In July 2023, CMS released the CY 2024 Medicare Physician Fee Schedule (“MPFS”) Proposed Rule (“MPFS Proposed Rule”). The MPFS Proposed Rule includes updates to payment policies, payment rates and other provisions for services reimbursed under the MPFS from January 1 through December 31, 2024. Under the MPFS Proposed Rule, the CY 2024 conversion factor, which is the base rate that is used to convert relative units into payment rates, would be reduced from $33.89 to $32.75, a decrease of 3.36%, due to budget neutrality rules and the adjustment provided for in the Consolidated Appropriations Act, 2023 (“CAA, 2023”). The CAA, 2023 provided for a 2.5% positive adjustment to the MPFS CY 2023 conversion factor and a 1.25% positive adjustment to the CY 2024 conversion factor, resulting in a 1.25% decrease in the proposed CY 2024 conversion from the CY 2023 conversion factor. We estimate the impact of the MPFS Proposed Rule should result in a reduction of less than $6 million to our FFS MPFS revenues. Because of the uncertainty associated with various factors that may influence our future MPFS payments, including legislative, regulatory or legal actions, volumes and case mix, as well as potential changes to the MPFS Proposed Rule, we cannot provide any assurances regarding our estimate of the impact of the proposed payment and policy changes.

*Public Health and Social Services Emergency Fund—*Our Hospital Operations and Ambulatory Care segments recognized grant income from federal and state programs associated with lost revenues and COVID‑related costs of $8 million and $94 million during the three months ended June 30, 2023 and 2022, respectively, and $11 million and $100 million during the six months ended June 30, 2023 and 2022, respectively. Grant income recognized by our Hospital Operations and Ambulatory Care segments is presented in grant income in our condensed consolidated statements of operations. With the termination of the public health emergency on May 11, 2023, there is no assurance or expectation that we will continue to receive or remain eligible for significant funding or assistance under the COVID Acts or similar measures in the future.

### PRIVATE INSURANCE

### Managed Care

We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full‑service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost‑effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non‑contracted healthcare providers for non‑emergency care. PPOs generally offer limited benefits to members who use non‑contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co‑pays, co‑insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high‑deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.

The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the three months ended June 30, 2023 and 2022 was $2.565 billion and $2.304 billion, respectively, and $5.068 billion and $4.742 billion during the six months ended June 30, 2023 and 2022, respectively. Our top 10 managed care payers generated 65% of our managed care net patient service revenues for the six months ended June 30, 2023. During the same period, national payers generated 43% of our managed care net patient service revenues; the remainder came from regional or local payers. At both June 30, 2023 and December 31, 2022, 66% of our net accounts receivable for our Hospital Operations segment were due from managed care payers.

Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per‑diem rates, discounted FFS rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient‑by‑patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at June 30, 2023, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $20 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop‑loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in‑house and discharged‑not‑final‑billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. We believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues during the six months ended June 30, 2023. In addition, on a corporate‑wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for these payers and other factors that affect the estimation process.

We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year‑over‑year aggregate managed care pricing improvements for some time, we have seen these improvements moderate in recent years, and we believe this moderation could continue into the future, subject to incremental pricing improvements to address inflationary pressures. In the six months ended June 30, 2023, our commercial managed care net inpatient revenue per admission from the hospitals in our Hospital Operations segment was approximately 95% higher than our aggregate yield on a per‑admission basis from government payers, including managed Medicare and Medicaid insurance plans.

### Indemnity

An indemnity‑based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.

### UNINSURED PATIENTS

Uninsured patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our uninsured patients are admitted through our hospitals’ emergency departments and often require high‑acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.

Self‑pay accounts receivable, which include amounts due from uninsured patients, as well as co‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance, pose significant collectability problems. At both June 30, 2023 and December 31, 2022, 5% of our net accounts receivable for our Hospital Operations segment was self‑pay. Further, a significant portion of our implicit price concessions relates to self‑pay amounts. We provide revenue cycle management services through Conifer, which is subject to various statutes and regulations regarding consumer protection in areas including finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Laws and Regulations Affecting Conifer’s Operations, of Part I of our Annual Report.

Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our implicit price concessions in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non‑emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self‑pay accounts, as well as co‑pay, co‑insurance and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical‑based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.

Over the longer term, several other initiatives we have previously announced should also help address the challenges associated with serving uninsured patients. For example, our *Compact with Uninsured Patients (“Compact”*) is designed to offer managed care‑style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. Under the *Compact*, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self‑pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for self‑pay accounts and other factors that affect the estimation process.

We also provide financial assistance through our charity and uninsured discount programs to uninsured patients who are unable to pay for the healthcare services they receive. Our policy is not to pursue collection of amounts determined to qualify for financial assistance; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care. Some states have also developed provider fee or other supplemental payment programs to mitigate the shortfall of Medicaid reimbursement compared to the cost of caring for Medicaid patients.

The initial expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions, along with reductions in Medicare and Medicaid reimbursement to healthcare providers, including us. However, we continue to provide uninsured discounts and charity care due to the failure of certain states to expand Medicaid coverage and for persons living in the country who are not permitted to enroll in a health insurance exchange or government healthcare insurance program.

The COVID Acts included a requirement that state Medicaid programs keep people continuously enrolled during the COVID‑19 public health emergency in exchange for a temporary increase to the Federal Medical Assistance Percentage. This continuous enrollment condition ended on March 31, 2023 and, on April 1, 2023, states were permitted to begin eligibility redeterminations on their Medicaid populations and disenroll individuals no longer eligible. The resulting volume of redeterminations has caused backlogs in the processing of new applications, which has increased the overall certification timeframe. We expect the certification timing will return to normal as these backlogs are resolved. Although we have not been materially adversely affected to date, any increase in the volume of uninsured patients could have an impact on our uncompensated care expense.

The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:

|  | Three Months Ended June 30, 2023 | 2022 | Six Months Ended June 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| Uninsured patients | $116 | $136 | $239 | $258 |
| Charity care patients | 28 | 19 | 52 | 40 |
| **Total** | **$144** | **$155** | **$291** | **$298** |

### RESULTS OF OPERATIONS

The following tables present our consolidated net operating revenues, operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, on a continuing operations basis:

| Net operating revenues: | Three Months Ended June 30, 2023 2022 | Six Months Ended June 30, 2023 2022 |
| --- | ---: | ---: |
| Hospital Operations | $3,922 $3,645 | $7,821 $7,443 |
| Ambulatory Care | 942 771 | 1,847 1,509 |
| Conifer | 323 333 | 647 657 |
| Inter-segment eliminations | (105) (111) | (212) (226) |
| **Net operating revenues** | **5,082** **4,638** | **10,103** **9,383** |
| **Grant income** | **8** **94** | **11** **100** |
| **Equity in earnings of unconsolidated affiliates** | **54** **54** | **104** **100** |
| Operating expenses: |  |  |
| Salaries, wages and benefits | 2,285 2,126 | 4,543 4,308 |
| Supplies | 891 811 | 1,782 1,596 |
| Other operating expenses, net | 1,125 1,006 | 2,218 1,948 |
| Depreciation and amortization | 213 216 | 430 419 |
| Impairment and restructuring charges, and acquisition-related costs | 16 57 | 37 73 |
| Litigation and investigation costs | 10 18 | 14 38 |
| Net gains on sales, consolidation and deconsolidation of facilities | — (1) | (13) — |
| **Operating income** | **$604** **$553** | **$1,207** **$1,201** |
|  | **Three Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2023** **2022** | **2023** **2022** |
| **Net operating revenues** | **100.0%** **100.0%** | **100.0%** **100.0%** |
| **Grant income** | **0.2%** **2.0%** | **0.1%** **1.1%** |
| **Equity in earnings of unconsolidated affiliates** | **1.1%** **1.2%** | **1.0%** **1.1%** |
| Operating expenses: |  |  |
| Salaries, wages and benefits | 45.0% 45.8% | 45.0% 45.9% |
| Supplies | 17.5% 17.5% | 17.6% 17.0% |
| Other operating expenses, net | 22.1% 21.7% | 22.0% 20.8% |
| Depreciation and amortization | 4.3% 4.7% | 4.2% 4.5% |
| Impairment and restructuring charges, and acquisition-related costs | 0.3% 1.2% | 0.4% 0.8% |
| Litigation and investigation costs | 0.2% 0.4% | 0.1% 0.4% |
| Net gains on sales, consolidation and deconsolidation of facilities | —% —% | (0.1)% —% |
| **Operating income** | **11.9%** **11.9%** | **11.9%** **12.8%** |

41

The following tables present our net operating revenues, operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, by operating segment on a continuing operations basis:

|  | Three Months Ended June 30, 2023 Hospital Operations | Ambulatory Care | Conifer | Six Months Ended June 30, 2023 Hospital Operations | Ambulatory Care | Conifer |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| **Net operating revenues** | **$3,817** | **$942** | **$323** | **$7,609** | **$1,847** | **$647** |
| **Grant income** | **7** | **1** | **—** | **10** | **1** | **—** |
| **Equity in earnings of unconsolidated affiliates** | **2** | **52** | **—** | **5** | **99** | **—** |
| Operating expenses: |  |  |  |  |  |  |
| Salaries, wages and benefits | 1,872 | 240 | 173 | 3,722 | 475 | 346 |
| Supplies | 636 | 253 | 2 | 1,269 | 510 | 3 |
| Other operating expenses, net | 930 | 132 | 63 | 1,840 | 252 | 126 |
| Depreciation and amortization | 176 | 27 | 10 | 357 | 54 | 19 |
| Impairment and restructuring charges, and acquisition-related costs | 9 | 2 | 5 | 23 | 5 | 9 |
| Litigation and investigation costs | 5 | 5 | — | 8 | 6 | — |
| Net gains on sales, consolidation and deconsolidation of facilities | — | — | — | — | (13) | — |
| **Operating income** | **$198** | **$336** | **$70** | **$405** | **$658** | **$144** |
| **Net operating revenues** | **100.0%** | **100.0%** | **100.0%** | **100.0%** | **100.0%** | **100.0%** |
| **Grant income** | **0.2%** | **0.1%** | **—%** | **0.1%** | **0.1%** | **—%** |
| **Equity in earnings of unconsolidated affiliates** | **0.1%** | **5.5%** | **—%** | **0.1%** | **5.4%** | **—%** |
| Operating expenses: |  |  |  |  |  |  |
| Salaries, wages and benefits | 49.0% | 25.5% | 53.6% | 48.9% | 25.7% | 53.5% |
| Supplies | 16.7% | 26.9% | 0.6% | 16.7% | 27.6% | 0.5% |
| Other operating expenses, net | 24.4% | 14.0% | 19.5% | 24.2% | 13.6% | 19.5% |
| Depreciation and amortization | 4.7% | 2.8% | 3.1% | 4.7% | 3.1% | 2.8% |
| Impairment and restructuring charges, and acquisition-related costs | 0.2% | 0.2% | 1.5% | 0.3% | 0.3% | 1.4% |
| Litigation and investigation costs | 0.1% | 0.5% | —% | 0.1% | 0.3% | —% |
| Net gains on sales, consolidation and deconsolidation of facilities | —% | —% | —% | —% | (0.7)% | —% |
| **Operating income** | **5.2%** | **35.7%** | **21.7%** | **5.3%** | **35.6%** | **22.3%** |

42

|  | Three Months Ended June 30, 2022 Hospital Operations | Ambulatory Care | Conifer | Six Months Ended June 30, 2022 Hospital Operations | Ambulatory Care | Conifer |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| **Net operating revenues** | **$3,534** | **$771** | **$333** | **$7,217** | **$1,509** | **$657** |
| **Grant income** | **92** | **2** | **—** | **96** | **4** | **—** |
| **Equity in earnings of unconsolidated affiliates** | **2** | **52** | **—** | **6** | **94** | **—** |
| Operating expenses: |  |  |  |  |  |  |
| Salaries, wages and benefits | 1,752 | 201 | 173 | 3,572 | 395 | 341 |
| Supplies | 605 | 205 | 1 | 1,188 | 406 | 2 |
| Other operating expenses, net | 840 | 100 | 66 | 1,614 | 205 | 129 |
| Depreciation and amortization | 179 | 28 | 9 | 346 | 55 | 18 |
| Impairment and restructuring charges, and acquisition-related costs | 42 | 5 | 10 | 54 | 8 | 11 |
| Litigation and investigation costs | 18 | — | — | 26 | — | 12 |
| Net gains on sales, consolidation and deconsolidation of facilities | (1) | — | — | — | — | — |
| **Operating income** | **$193** | **$286** | **$74** | **$519** | **$538** | **$144** |
| **Net operating revenues** | **100.0%** | **100.0%** | **100.0%** | **100.0%** | **100.0%** | **100.0%** |
| **Grant income** | **2.6%** | **0.3%** | **—%** | **1.3%** | **0.3%** | **—%** |
| **Equity in earnings of unconsolidated affiliates** | **0.1%** | **6.7%** | **—%** | **0.1%** | **6.2%** | **—%** |
| Operating expenses: |  |  |  |  |  |  |
| Salaries, wages and benefits | 49.6% | 26.1% | 52.0% | 49.5% | 26.2% | 51.9% |
| Supplies | 17.1% | 26.6% | 0.3% | 16.5% | 26.9% | 0.3% |
| Other operating expenses, net | 23.7% | 13.0% | 19.8% | 22.3% | 13.6% | 19.7% |
| Depreciation and amortization | 5.1% | 3.6% | 2.7% | 4.8% | 3.6% | 2.7% |
| Impairment and restructuring charges, and acquisition-related costs | 1.2% | 0.6% | 3.0% | 0.7% | 0.5% | 1.7% |
| Litigation and investigation costs | 0.5% | —% | —% | 0.4% | —% | 1.8% |
| Net gains on sales, consolidation and deconsolidation of facilities | —% | —% | —% | —% | —% | —% |
| **Operating income** | **5.5%** | **37.1%** | **22.2%** | **7.2%** | **35.7%** | **21.9%** |

Consolidated net operating revenues increased by $444 million and $720 million, or 9.6% and 7.7%, for the three and six months ended June 30, 2023, respectively, compared to the three and six months ended June 30, 2022. Our Hospital Operations segment’s net operating revenues net of inter‑segment eliminations increased by $283 million and $392 million, or 8.0% and 5.4%, for the three and six months ended June 30, 2023 compared to the same periods in 2022. The increases for both periods in 2023 were primarily driven by the opening of our PMC Fort Mill Hospital in September 2022, higher patient volumes, the adverse impacts associated with a cybersecurity incident in the 2022 period and negotiated commercial rate increases. Our Hospital Operations segment also recognized income from state grants totaling $7 million and $10 million during the three and six months ended June 30, 2023, respectively, and income totaling $92 million and $96 million from combined federal and state grants during the same periods in 2022, respectively, none of which is included in net operating revenues.

### RESULTS OF OPERATIONS BY SEGMENT

Our operations are reported in three segments:

- Hospital Operations, which is comprised of our acute care and specialty hospitals, a network of employed physicians and ancillary outpatient facilities;
- Ambulatory Care, which is comprised of USPI’s ASCs and surgical hospitals; and
- Conifer, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients.

### Hospital Operations Segment

The following tables present operating statistics, revenues and expenses of our hospitals and related outpatient facilities on a same‑hospital basis, unless otherwise indicated:

| Admissions, Patient Days and Surgeries | Same-Hospital Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) | 2023 | Same-Hospital Six Months Ended June 30, 2022 |  | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Number of hospitals (at end of period) | 60 | 60 | — | (1) | 60 | 60 | — | (1) |
| Total admissions | 131,955 | 128,068 | 3.0% |  | 265,168 | 255,850 | 3.6% |  |
| Adjusted admissions | 246,689 | 239,031 | 3.2% |  | 489,932 | 466,964 | 4.9% |  |
| Paying admissions (excludes charity and uninsured) | 126,118 | 121,823 | 3.5% |  | 253,525 | 243,620 | 4.1% |  |
| Charity and uninsured admissions | 5,837 | 6,245 | (6.5)% |  | 11,643 | 12,230 | (4.8)% |  |
| Admissions through emergency department | 98,820 | 96,136 | 2.8% |  | 199,548 | 193,820 | 3.0% |  |
| Paying admissions as a percentage of total admissions | 95.6% | 95.1% | 0.5% | (1) | 95.6% | 95.2% | 0.4% | (1) |
| Charity and uninsured admissions as a percentage of total admissions | 4.4% | 4.9% | (0.5)% | (1) | 4.4% | 4.8% | (0.4)% | (1) |
| Emergency department admissions as a percentage of total admissions | 74.9% | 75.1% | (0.2)% | (1) | 75.3% | 75.8% | (0.5)% | (1) |
| Surgeries — inpatient | 34,371 | 33,749 | 1.8% |  | 68,219 | 66,657 | 2.3% |  |
| Surgeries — outpatient | 52,923 | 53,638 | (1.3)% |  | 105,176 | 104,896 | 0.3% |  |
| Total surgeries | 87,294 | 87,387 | (0.1)% |  | 173,395 | 171,553 | 1.1% |  |
| Patient days — total | 674,612 | 658,995 | 2.4% |  | 1,375,585 | 1,364,618 | 0.8% |  |
| Adjusted patient days | 1,208,906 | 1,192,999 | 1.3% |  | 2,438,954 | 2,417,823 | 0.9% |  |
| Average length of stay (days) | 5.11 | 5.15 | (0.8)% |  | 5.19 | 5.33 | (2.6)% |  |
| Licensed beds (at end of period) | 15,372 | 15,391 | (0.1)% |  | 15,372 | 15,391 | (0.1)% |  |
| Average licensed beds | 15,372 | 15,382 | (0.1)% |  | 15,372 | 15,389 | (0.1)% |  |
| Utilization of licensed beds | 48.2% | 47.1% | 1.1% | (1) | 49.4% | 49.0% | 0.4% | (1) |

(1) The change is the difference between the 2023 and 2022 amounts presented.

| Outpatient Visits | Same-Hospital Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) | 2023 | Same-Hospital Six Months Ended June 30, 2022 |  | Increase (Decrease) |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total visits | 1,394,667 | 1,413,222 | (1.3)% |  | 2,768,498 | 2,786,410 | (0.6)% |  |
| Paying visits (excludes charity and uninsured) | 1,322,729 | 1,332,124 | (0.7)% |  | 2,625,222 | 2,627,573 | (0.1)% |  |
| Charity and uninsured visits | 71,938 | 81,098 | (11.3)% |  | 143,276 | 158,837 | (9.8)% |  |
| Emergency department visits | 540,826 | 541,090 | —% |  | 1,067,356 | 1,041,755 | 2.5% |  |
| Surgery visits | 52,923 | 53,638 | (1.3)% |  | 105,176 | 104,896 | 0.3% |  |
| Paying visits as a percentage of total visits | 94.8% | 94.3% | 0.5% | (1) | 94.8% | 94.3% | 0.5% | (1) |
| Charity and uninsured visits as a percentage of total visits | 5.2% | 5.7% | (0.5)% | (1) | 5.2% | 5.7% | (0.5)% | (1) |

(1) The change is the difference between the 2023 and 2022 amounts presented.

| Revenues | Same-Hospital Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) 2023 | Same-Hospital Six Months Ended June 30, 2022 |  | Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total segment net operating revenues | $3,794 | $3,528 | 7.5% | $7,566 | $7,210 | 4.9% |
| **Selected revenue data – hospitals and related outpatient facilities:** |  |  |  |  |  |  |
| Net patient service revenues | $3,590 | $3,344 | 7.4% | $7,137 | $6,851 | 4.2% |
| Net patient service revenue per adjusted admission | $14,553 | $13,990 | 4.0% | $14,567 | $14,671 | (0.7)% |
| Net patient service revenue per adjusted patient day | $2,970 | $2,803 | 6.0% | $2,926 | $2,834 | 3.2% |

| Selected Operating Expenses | Same-Hospital Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) 2023 | Same-Hospital Six Months Ended June 30, 2022 |  | Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Salaries, wages and benefits | $1,864 | $1,752 | 6.4% | $3,707 | $3,574 | 3.7% |
| Supplies | 635 | 605 | 5.0% | 1,266 | 1,189 | 6.5% |
| Other operating expenses | 922 | 837 | 10.2% | 1,825 | 1,610 | 13.4% |
|  | **$3,421** | **$3,194** | **7.1%** | **$6,798** | **$6,373** | **6.7%** |

| Selected Operating Expenses as a Percentage of Net Operating Revenues 2023 | Same-Hospital Three Months Ended June 30, 2022 |  | Increase (Decrease)(1) 2023 | Same-Hospital Six Months Ended June 30, 2022 |  | Increase (Decrease)(1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Salaries, wages and benefits | 49.1% | 49.7% | (0.6)% | 49.0% | 49.6% | (0.6)% |
| Supplies | 16.7% | 17.1% | (0.4)% | 16.7% | 16.5% | 0.2% |
| Other operating expenses | 24.3% | 23.7% | 0.6% | 24.1% | 22.3% | 1.8% |

(1) The change is the difference between the 2023 and 2022 amounts presented.

#### Revenues

Same‑hospital net operating revenues increased by $266 million, or 7.5%, during the three months ended June 30, 2023 compared to the three months ended June 30, 2022, primarily due to higher patient volumes, negotiated commercial rate increases and the adverse impacts associated with a cybersecurity incident in the 2022 period. Our Hospital Operations segment also recognized income totaling $7 million and $92 million from federal and state grants in the three months ended June 30, 2023 and 2022, respectively, which is not included in net operating revenues. Same‑hospital adjusted admissions increased 3.2% in the three months ended June 30, 2023 compared to the same period in 2022.

Same‑hospital net operating revenues increased by $356 million, or 4.9%, during the six months ended June 30, 2023 compared to the six months ended June 30, 2022, primarily due to higher patient volumes, negotiated commercial rate increases and the adverse impacts associated with a cybersecurity incident in the 2022 period. Our Hospital Operations segment also recognized income totaling $10 million and $96 million from federal and state grants in the six months ended June 30, 2023 and 2022, respectively, which is not included in net operating revenues. Same‑hospital adjusted admissions increased 4.9% in the six months ended June 30, 2023 compared to the same period in 2022.

The following table presents our consolidated net accounts receivable by payer:

|  | June 30, 2023 | December 31, 2022 |
| --- | ---: | ---: |
| Medicare | $149 | $166 |
| Medicaid | 54 | 44 |
| Net cost report settlements receivable and valuation allowances | 77 | 48 |
| Managed care | 1,652 | 1,661 |
| Self-pay uninsured | 37 | 35 |
| Self-pay balance after insurance | 91 | 92 |
| Estimated future recoveries | 154 | 149 |
| Other payers | 295 | 315 |
| Total Hospital Operations | 2,509 | 2,510 |
| Ambulatory Care | 405 | 433 |
| **Accounts receivable, net** | **$2,914** | **$2,943** |

The collection of accounts receivable is a key area of focus for our business. At June 30, 2023 and December 31, 2022, our Hospital Operations segment collection rate on self‑pay accounts was approximately 29.8% and 29.5%, respectively. Our self‑pay collection rate includes payments made by patients, including co‑pays, co‑insurance amounts and deductibles paid by patients with insurance. Based on our accounts receivable from uninsured patients and co‑pays, co‑insurance amounts and deductibles owed to us by patients with insurance at June 30, 2023, a 10% decrease or increase in our self‑pay collection rate, or approximately 3.0%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to patient accounts receivable of approximately $11 million. There are various factors that can impact collection trends, such as changes in the economy and inflation, which in turn have an impact on unemployment rates and the number of uninsured and underinsured patients, the volume of patients through our emergency departments, the increased burden of co‑pays and deductibles to be made by patients with insurance, and business practices related to collection efforts. These factors, many of which were affected by the pandemic, continuously change and can have an impact on collection trends and our estimation process.

We also typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations segment collection rate from managed care payers was approximately 97.2% and 95.7% at June 30, 2023 and December 31, 2022. respectively.

We manage our implicit price concessions using hospital‑specific goals and benchmarks such as (1) total cash collections, (2) point‑of‑service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following table presents the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations segment of $2.432 billion and $2.462 billion at June 30, 2023 and December 31, 2022, respectively. Cost report settlements receivable, net of payables and related valuation allowances, of $77 million and $48 million at June 30, 2023 and December 31, 2022, respectively, are excluded from the table.

| At June 30, 2023 | Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| 0-60 days | 90% | 43% | 56% | 22% | 51% |
| 61-120 days | 4% | 27% | 17% | 14% | 16% |
| 121-180 days | 3% | 14% | 11% | 8% | 10% |
| Over 180 days | 3% | 16% | 16% | 56% | 23% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |
| **At December 31, 2022** |  |  |  |  |  |
| 0-60 days | 90% | 34% | 56% | 22% | 50% |
| 61-120 days | 5% | 28% | 16% | 15% | 15% |
| 121-180 days | 2% | 16% | 9% | 7% | 9% |
| Over 180 days | 3% | 22% | 19% | 56% | 26% |
| **Total** | **100%** | **100%** | **100%** | **100%** | **100%** |

46

Conifer continues to implement revenue cycle initiatives intended to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre‑registration, registration, verification of eligibility and benefits, liability identification and collections at point‑of‑service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.

Patient advocates from Conifer’s Eligibility and Enrollment Services program (“EES”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as Medicaid pending, under the EES, net of appropriate implicit price concessions. Based on recent trends, approximately 97% of all accounts in the EES are ultimately approved for benefits under a government program, such as Medicaid.

The following table presents the approximate amount of accounts receivable in the EES still awaiting determination of eligibility under a government program by aging category:

|  | June 30, 2023 | December 31, 2022 |
| --- | ---: | ---: |
| 0-60 days | $84 | $79 |
| 61-120 days | 16 | 18 |
| 121-180 days | 7 | 3 |
| Over 180 days | 7 | 6 |
| **Total** | **$114** | **$106** |

#### Salaries, Wages and Benefits

Same‑hospital salaries, wages and benefits expense increased by $112 million, or 6.4%, in the three months ended June 30, 2023 compared to the same period in 2022. This change was primarily attributable to merit increases for certain of our employees and increased employee benefits, recruiting and retention costs in the 2023 period, as well as higher incentive compensation expense. These factors were partially offset by a decrease in contract labor expense, driven by our focus on recruiting initiatives. As a percentage of net operating revenues, same‑hospital salaries, wages and benefits decreased by 60 basis points to 49.1% in the three months ended June 30, 2023 compared to the three months ended June 30, 2022. Salaries, wages and benefits expense for the three months ended June 30, 2023 and 2022 included stock‑based compensation expense of $13 million and $14 million, respectively.

Same‑hospital salaries, wages and benefits expense increased by $133 million, or 3.7%, in the six months ended June 30, 2023 compared to the same period in 2022. This increase was primarily attributable to the same factors that affected the three-month period. As a percentage of net operating revenues, same‑hospital salaries, wages and benefits decreased by 60 basis points to 49.0% in the six months ended June 30, 2023 compared to the three months ended June 30, 2022. Salaries, wages and benefits expense for the three months ended June 30, 2023 and 2022 included stock‑based compensation expense of $23 million and $26 million, respectively.

#### Supplies

Same‑hospital supplies expense increased by $30 million, or 5.0%, in the three months ended June 30, 2023 compared to the same period in 2022. This increase was driven by higher patient volumes during the three‑month period in 2023, as well as the impact of general market conditions and inflation. Same‑hospital supplies expense as a percentage of net operating revenues decreased by 40 basis points to 16.7% in the three months ended June 30, 2023 compared to the three months ended June 30, 2022, reflecting our continued focus on cost‑efficiency measures.

Same‑hospital supplies expense increased by $77 million, or 6.5%, in the six months ended June 30, 2023 compared to the same period in 2022. This increase was driven by higher patient and surgical volumes during the six-month period in 2023, as well as the impact of general market conditions and inflation. Improvements realized from our focus on cost‑efficiency measures, partially offset the increase in same-hospital supplies expense during the 2023 period. Same‑hospital supplies expense as a percentage of net operating revenues increased by 20 basis points to 16.7% in the six months ended June 30, 2023 compared to the six months ended June 30, 2022.

We strive to control supplies expense through product standardization, consistent contract terms and end‑to‑end contract management, improved utilization, bulk purchases, focused spending with a smaller number of vendors and operational improvements.

#### Other Operating Expenses, Net

Same‑hospital other operating expenses increased by $85 million, or 10.2%, in the three months ended June 30, 2023 compared to the same period in 2022. The changes in other operating expenses included an increase in malpractice expense of $41 million and $25 million more in medical fees during 2023. Same‑hospital other operating expenses as a percentage of net operating revenues increased by 60 basis points to 24.3% for the three months ended June 30, 2023 compared to 23.7% for the three months ended June 30, 2022.

Same‑hospital other operating expenses increased by $215 million, or 13.4%, in the six months ended June 30, 2023 compared to the same period in 2022. Other operating expenses for the six months ended June 30, 2022 were reduced by a gain of $69 million from the sale of several office buildings; whereas net gains recognized during the same period in 2023 were $10 million. The changes in other operating expenses during the six months ended June 30, 2023 also included:

- an increase of $50 million in malpractice expense;
- $51 million more in medical fees; and
- an $18 million increase in repair and maintenance costs.

Same‑hospital other operating expenses as a percentage of net operating revenues increased by 180 basis points to 24.1% for the six months ended June 30, 2023 compared to 22.3% for the six months ended June 30, 2022.

### Ambulatory Care Segment

Our Ambulatory Care segment is comprised of USPI’s ASCs and surgical hospitals. USPI operates its surgical facilities in partnership with local physicians and, in many of these facilities, a health system partner. In most cases, we hold ownership interests in the facilities and operate them through a separate legal entity. USPI operates facilities on a day‑to‑day basis through management services contracts. Our sources of earnings from each facility consist of:

- management and administrative services revenues from the facilities USPI operates through management services contracts, usually computed as a percentage of each facility’s net revenues; and
- our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by USPI.

Our role as an owner and day‑to‑day manager provides us with significant influence over the operations of each facility. For many of the facilities our Ambulatory Care segment holds an ownership interest in (159 of 479 facilities at June 30, 2023), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. USPI controls 320 of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries. The net profit attributable to owners other than USPI is classified within net income available to noncontrolling interests. For unconsolidated affiliates, our statements of operations reflect our earnings in two line items:

- *equity in earnings of unconsolidated affiliates—*our share of the net income (loss) of each facility, which is based on the facility’s net income (loss) and the percentage of the facility’s outstanding equity interests owned by USPI; and
- *management and administrative services revenues, which is included in our net operating revenues—*income we earn in exchange for managing the day‑to‑day operations of each facility, usually computed as a percentage of each facility’s net revenues.

Our Ambulatory Care segment’s operating income is driven by the performance of all facilities USPI operates and by USPI’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 67% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses, which is why we disclose certain statistical and financial data on a pro forma systemwide basis that includes both consolidated and unconsolidated (equity method) facilities.

#### Results of Operations

The following table presents selected revenue and expense information for our Ambulatory Care segment:

|  | Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) 2023 | Six Months Ended June 30, 2022 |  | Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net operating revenues | $942 | $771 | 22.2% | $1,847 | $1,509 | 22.4% |
| Grant income | $1 | $2 | (50.0)% | $1 | $4 | (75.0)% |
| Equity in earnings of unconsolidated affiliates | $52 | $52 | —% | $99 | $94 | 5.3% |
| Salaries, wages and benefits | $240 | $201 | 19.4% | $475 | $395 | 20.3% |
| Supplies | $253 | $205 | 23.4% | $510 | $406 | 25.6% |
| Other operating expenses, net | $132 | $100 | 32.0% | $252 | $205 | 22.9% |

#### Revenues

Our Ambulatory Care segment’s net operating revenues increased by $171 million, or 22.2%, during the three months ended June 30, 2023 compared to the same period in 2022. The change was driven by an increase from acquisitions of $106 million, as well as higher same‑facility net operating revenues of $76 million due primarily to higher surgical patient volumes and negotiated commercial rate increases. These increases were partially offset by a decrease of $11 million due primarily to the closure and deconsolidation of certain facilities. Our Ambulatory Care segment also recognized grant income from federal grants totaling $1 million and $2 million during the three months ended June 30, 2023 and 2022, respectively, which is not included in net operating revenues.

Ambulatory Care net operating revenues increased by $338 million, or 22.4%, during the six months ended June 30, 2023 compared to the same period in 2022. The change was driven by an increase from acquisitions of $204 million, as well as higher same‑facility net operating revenues of $161 million due primarily to higher surgical patient volumes and negotiated commercial rate increases. These increases were partially offset by a decrease of $27 million due primarily to the closure and deconsolidation of certain facilities. Our Ambulatory Care segment also recognized grant income from federal grants totaling $1 million and $4 million during the six months ended June 30, 2023 and 2022, respectively, which is not included in net operating revenues.

#### Salaries, Wages and Benefits

Salaries, wages and benefits expense increased by $39 million, or 19.4%, during the three months ended June 30, 2023 compared to the same period in 2022. This change was driven by an increase from acquisitions of $22 million, as well as an increase in same‑facility salaries, wages and benefits expense of $20 million, partially offset by a decrease of $3 million primarily due to the closure and deconsolidation of certain facilities. As a percentage of net operating revenues, salaries, wages and benefits expense decreased to 25.5% for the three months ended June 30, 2023 from 26.1% for the same period in 2022 due to enhanced labor management processes. Salaries, wages and benefits expense included $5 million and $3 million of stock‑based compensation expense in the three months ended June 30, 2023 and 2022, respectively.

Salaries, wages and benefits expense increased by $80 million, or 20.3%, during the six months ended June 30, 2023 compared to the same period in 2022. This change was driven by an increase from acquisitions of $42 million and an increase in same‑facility salaries, wages and benefits expense of $43 million due primarily to higher surgical patient volumes, partially offset by a decrease of $5 million due primarily to the aforementioned closure and deconsolidation of certain facilities. As a percentage of net operating revenues, salaries, wages and benefits expense decreased to 25.7% for the six months ended June 30, 2023 from 26.2% for the same period in 2022. Salaries, wages and benefits expense included $9 million and $6 million of stock‑based compensation expense in the six months ended June 30, 2023 and 2022, respectively.

#### Supplies

Supplies expense increased by $48 million, or 23.4%, during the three months ended June 30, 2023 compared to the same period in 2022. The change was driven by an increase from acquisitions of $28 million, as well as an increase in same‑facility supplies expense of $22 million due primarily to higher case volume, partially offset by a decrease of $2 million attributable to the closure and deconsolidation of certain facilities. Supplies expense as a percentage of net operating revenues was 26.9% for the three months ended June 30, 2023 compared to 26.6% for the same period in 2022.

Supplies expense increased by $104 million, or 25.6%, during the six months ended June 30, 2023 compared to the same period in 2022. The change was driven by an increase from acquisitions of $61 million, as well as an increase in same‑facility supplies expense of $47 million due primarily to an increase in surgical cases at our consolidated centers, partially offset by a decrease of $4 million due to the closure and deconsolidation of certain facilities. Supplies expense as a percentage of net operating revenues was 27.6% for the six months ended June 30, 2023 compared to 26.9% for the same period in 2022.

#### Other Operating Expenses, Net

Other operating expenses increased by $32 million, or 32.0%, during the three months ended June 30, 2023 compared to the same period in 2022. The change was driven by an increase from acquisitions of $17 million and an increase in same‑facility other operating expenses of $16 million, partially offset by a decrease of $1 million attributable primarily to the closure and deconsolidation of certain facilities. Other operating expenses as a percentage of net operating revenues increased to 14.0% for the three months ended June 30, 2023 from 13.0% for the same period in 2022.

Other operating expenses increased by $47 million, or 22.9%, during the six months ended June 30, 2023 compared to the same period in 2022. The change was driven by an increase from acquisitions of $32 million and an increase in same‑facility other operating expenses of $17 million, partially offset by a decrease of $2 million primarily due to the closure and deconsolidation of certain facilities. Other operating expenses as a percentage of net operating revenues were flat at 13.6% for both of the six-month periods ended June 30, 2023 and 2022.

#### Facility Growth

The following table presents the year‑over‑year changes in our same‑facility revenue and cases on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.

|  | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2023 |
| --- | ---: | ---: |
| Net revenues | 9.8% | 9.6% |
| Cases | 6.6% | 7.2% |
| Net revenue per case | 2.9% | 2.2% |

#### Joint Ventures with Health System Partners

USPI’s business model is to jointly own its facilities with local physicians and, in many of these facilities, a health system partner. The table below provides information about the ownership structure of the facilities operated by our Ambulatory Care segment:

|  | June 30, 2023 |
| --- | ---: |
| Owned with a health system partner | 208 |
| Owned without a health system partner | 271 |
| **Total** | **479** |

#### Facility Acquisitions and Investment

The table below presents the aggregate amounts we paid to acquire various ownership interests in ambulatory care facilities:

|  | Six Months Ended June 30, 2023 | 2022 |
| --- | ---: | ---: |
| Controlling interests | $96 | $66 |
| Equity investment in unconsolidated affiliates and consolidated facilities | 9 | 14 |
| **Total** | **$105** | **$80** |

50

The table below reflects the change in the number of facilities operated by our Ambulatory Care segment since December 31, 2022:

|  | Six Months Ended June 30, 2023 |
| --- | ---: |
| Acquisitions | 11 |
| De novo | 6 |
| Dispositions/Mergers | (4) |
| **Total increase in number of facilities operated** | **13** |

During the six months ended June 30, 2023, we acquired controlling interests in eleven ASCs, three located in Ohio, two located in Texas and one each located in Arizona, California, Maryland, Missouri, South Carolina and Washington, in which we did not have a previous investment. Ten of these facilities are jointly owned with physicians, and one is jointly owned with a health system partner and physicians. We also acquired controlling ownership interests in four previously unconsolidated ASCs, each located in a different state, during the six months ended June 30, 2023. We paid an aggregate of $96 million to acquire controlling ownership interests in all of the aforementioned facilities.

We also regularly engage in the purchase of equity interests with respect to our investments in unconsolidated affiliates and consolidated facilities that do not result in a change in control. These transactions are primarily the acquisitions of equity interests in ASCs and the investment of additional cash in facilities that need capital for new acquisitions, new construction or other business growth opportunities. During the six months ended June 30, 2023, we invested approximately $9 million in such transactions.

### Conifer Segment

The following table presents selected revenue and expense information for our Conifer segment:

|  | Three Months Ended June 30, 2023 | 2022 | Increase (Decrease) 2023 | Six Months Ended June 30, 2022 |  | Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue cycle and other services – Tenet | $105 | $111 | (5.4)% | $212 | $226 | (6.2)% |
| Revenue cycle and other services – other customers | $218 | $222 | (1.8)% | $435 | $431 | 0.9% |
| Salaries, wages and benefits | $173 | $173 | —% | $346 | $341 | 1.5% |
| Supplies | $2 | $1 | 100.0% | $3 | $2 | 50.0% |
| Other operating expenses | $63 | $66 | (4.5)% | $126 | $129 | (2.3)% |

#### Revenues

Our Conifer segment’s revenues from third‑party clients, which revenues are not eliminated in consolidation, decreased by $4 million, or 1.8%, for the three months ended June 30, 2023 compared to the same period in 2022. Our Conifer segment’s revenues from third‑party clients, which revenues are not eliminated in consolidation, increased by $4 million, or 0.9%, for the six months ended June 30, 2023 compared to the same period in 2022. The decline in revenues from Tenet in the 2023 periods reflects previously announced contract changes with Tenet hospitals.

#### Salaries, Wages and Benefits

Salaries, wages and benefits expense for Conifer in the three months ended June 30, 2023 were consistent with the expense incurred during the same period in 2022. Salaries, wages and benefits expense included stock‑based compensation expense of $1 million in each of the three-month periods ended June 30, 2023 and 2022.

Salaries, wages and benefits expense for Conifer increased by $5 million, or 1.5%, in the six months ended June 30, 2023 compared to the same period in 2022, primarily due to new business expansion, planned staffing increases and annual merit increases for certain of our employees, partially offset by the transition of various administrative functions to our GBC in the Philippines. Salaries, wages and benefits expense included stock‑based compensation expense of $1 million and $2 million in the six months ended June 30, 2023 and 2022, respectively.

#### Supplies

Conifer’s supplies expenses during the three and six months ended June 30, 2023 were consistent with the three and six months ended June 30, 2022.

#### Other Operating Expenses, Net

Our Conifer segment’s other operating expenses decreased by $3 million, or 4.5%, during the three months ended June 30, 2023 and decreased by $3 million, or 2.3%, during the six months ended June 30, 2023 compared to the same periods in 2022. The decreases in both periods were primarily driven by client divestitures.

### Consolidated

#### Impairment and Restructuring Charges, and Acquisition-Related Costs

The following table presents information about our impairment and restructuring charges, and acquisition‑related costs:

| Consolidated: | Three Months Ended June 30, 2023 | 2022 | Six Months Ended June 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| Impairment charges | $1 | $5 | $2 | $6 |
| Restructuring charges | 13 | 49 | 31 | 61 |
| Acquisition-related costs | 2 | 3 | 4 | 6 |
| **Total impairment and restructuring charges, and acquisition-related costs** | **$16** | **$57** | **$37** | **$73** |
| **By segment:** |  |  |  |  |
| Hospital Operations | $9 | $42 | $23 | $54 |
| Ambulatory Care | 2 | 5 | 5 | 8 |
| Conifer | 5 | 10 | 9 | 11 |
| **Total impairment and restructuring charges, and acquisition-related costs** | **$16** | **$57** | **$37** | **$73** |

During the three months ended June 30, 2023, restructuring charges consisted of $7 million of legal costs related to the sale of certain businesses, $3 million related to the transition of various administrative functions to our GBC, $2 million of employee severance costs and $1 million of other restructuring costs. Restructuring charges for the three months ended June 30, 2022 consisted of $16 million of employee severance costs, $3 million related to the transition of various administrative functions to our GBC, $21 million related to contract and lease termination fees, and $9 million of other restructuring costs. Acquisition‑related costs consisted entirely of transaction costs for both of the three-month periods ended June 30, 2023 and 2022.

During the six months ended June 30, 2023, restructuring charges consisted of $11 million of legal costs related to the sale of certain businesses, $7 million related to the transition of various administrative functions to our GBC, $6 million of employee severance costs and $7 million of other restructuring costs. Restructuring charges for the six months ended June 30, 2022 consisted of $21 million of employee severance costs, $5 million related to the transition of various administrative functions to our GBC, $22 million related to contract and lease termination fees, and $13 million of other restructuring costs. Acquisition‑related costs consisted entirely of transaction costs for both of the six-month periods ended June 30, 2023 and 2022.

#### Litigation and Investigation Costs

Litigation and investigation costs were $10 million and $18 million during the three months ended June 30, 2023 and 2022, respectively, and $14 million and $38 million, during the three months ended June 30, 2023 and 2022, respectively.

#### Net Gains on Sales, Consolidation and Deconsolidation of Facilities

There were no gains or losses related to the sale, consolidation or deconsolidation of facilities recognized during the three months ended June 30, 2023 and a gain of $1 million recognized during the three months ended June 30, 2022. We recorded net gains on the sale, consolidation and deconsolidation of facilities of $13 million during the six months ended June 30, 2023, primarily related to the consolidation of facilities by our Ambulatory Care segment. There were no gains or losses from the sale, consolidation or deconsolidation of facilities during the six months ended June 30, 2022.

#### Interest Expense

Interest expense for the three and six months ended June 30, 2023 was $226 million and $447 million, respectively, compared to $222 million and $449 million for the same periods in 2022.

#### Loss from Early Extinguishment of Debt

We recorded losses from the early extinguishment of debt totaling $11 million during the three and six months ended June 30, 2023. These losses related to the redemption of all of the outstanding principal of our September 2024 Senior Secured First Lien Notes and our July 2024 Senior Secured First Lien Notes during the three months ended June 30, 2023.

During the three and six months ended June 30, 2022, we incurred aggregate losses from early extinguishment of debt of $66 million and $109 million, respectively. These losses related to the redemption of our 7.500% senior secured first lien notes due 2025 in February 2022, open market purchases of our 6.750% senior unsecured notes due 2023 (“2023 Senior Unsecured Notes”) during the six months ended June 30, 2022 and the redemption in full of the 2023 Senior Unsecured Notes in June 2022, in all cases in advance of the notes’ maturity dates.

In all of the 2023 and 2022 periods, the losses from the early extinguishment of debt primarily related to the differences between the purchase or redemption prices and the par values of the notes, as well as the write‑off of associated unamortized issuance costs.

#### Income Tax Expense

During the three months ended June 30, 2023 and 2022, we recorded income tax expense of $80 million and $86 million on pre-tax income of $373 million and $265 million, respectively, and recorded income tax expense of $164 million and $185 million on pre-tax income of $753 million and $643 million during the six months ended June 30, 2023 and 2022, respectively. During the six months ended June 30, 2023 and 2022, we recorded income tax expense of $42 million and $77 million, respectively, to increase the valuation allowance for interest expense carryforwards as a result of the limitation on business interest expense.

A reconciliation between the amount of reported income tax expense and the amount computed by multiplying income from continuing operations before income taxes by the statutory federal tax rate is presented below:

|  | Three Months Ended June 30, 2023 | 2022 | Six Months Ended June 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| Tax expense at statutory federal rate of 21% | $78 | $56 | $158 | $135 |
| State income taxes, net of federal income tax benefit | 12 | 11 | 28 | 25 |
| Tax benefit attributable to noncontrolling interests | (35) | (28) | (67) | (57) |
| Nondeductible goodwill | — | 1 | — | 1 |
| Stock-based compensation tax benefit | (2) | (1) | (4) | (3) |
| Changes in valuation allowance | 23 | 45 | 42 | 77 |
| Other items | 4 | 2 | 7 | 7 |
| **Income tax expense** | **$80** | **$86** | **$164** | **$185** |

#### Net Income Available to Noncontrolling Interests

Net income available to noncontrolling interests was $170 million for the three months ended June 30, 2023 compared to $141 million for the three months ended June 30, 2022. Net income available to noncontrolling interests for the 2023 period was comprised of $139 million related to our Ambulatory Care segment, $22 million related to our Conifer segment and $9 million related to our Hospital Operations segment.

Net income available to noncontrolling interests was $323 million for the six months ended June 30, 2023 compared to $281 million for the six months ended June 30, 2022. Net income available to noncontrolling interests for the 2023 period was comprised of $265 million related to our Ambulatory Care segment, $44 million related to our Conifer segment and $14 million related to our Hospital Operations segment.

### ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES

As noted in the introduction to MD&A, we use certain non‑GAAP financial measures, including Adjusted EBITDA, in this report and in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements. We believe Adjusted EBITDA is useful to investors and analysts because it presents additional information about our financial performance. Investors, analysts, company management and our board of directors utilize this non‑GAAP measure, in addition to GAAP measures, to track our financial and operating performance and compare that performance to peer companies, which utilize similar non‑GAAP measures in their presentations. The human resources committee of our board of directors also uses certain non‑GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. We believe that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non‑GAAP measures, as factors in determining the estimated fair value of shares of our common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. We do not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non‑GAAP Adjusted EBITDA measure we utilize may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating our financial performance.

The following table presents the reconciliation of Adjusted EBITDA to net income available to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term):

|  | Three Months Ended June 30, 2023 | 2022 | Six Months Ended June 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| **Net income available to Tenet Healthcare Corporation common shareholders** | **$123** | **$38** | **$266** | **$178** |
| Less: Net income available to noncontrolling interests | (170) | (141) | (323) | (281) |
| Income from discontinued operations, net of tax | — | — | — | 1 |
| Income from continuing operations | 293 | 179 | 589 | 458 |
| Income tax expense | (80) | (86) | (164) | (185) |
| Loss from early extinguishment of debt | (11) | (66) | (11) | (109) |
| Other non-operating income, net | 6 | — | 4 | — |
| Interest expense | (226) | (222) | (447) | (449) |
| Operating income | 604 | 553 | 1,207 | 1,201 |
| Litigation and investigation costs | (10) | (18) | (14) | (38) |
| Net gains on sales, consolidation and deconsolidation of facilities | — | 1 | 13 | — |
| Impairment and restructuring charges, and acquisition-related costs | (16) | (57) | (37) | (73) |
| Depreciation and amortization | (213) | (216) | (430) | (419) |
| **Adjusted EBITDA** | **$843** | **$843** | **$1,675** | **$1,731** |
| **Net operating revenues** | **$5,082** | **$4,638** | **$10,103** | **$9,383** |
| **Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues** | **2.4%** | **0.8%** | **2.6%** | **1.9%** |
| **Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)** | **16.6%** | **18.2%** | **16.6%** | **18.4%** |

### LIQUIDITY AND CAPITAL RESOURCES

### CASH REQUIREMENTS

There have been no material changes to our obligations to make future cash payments under scheduled contractual obligations, such as debt and lease agreements, and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the matters set forth below and the additional lease obligations and other long-term debt transactions disclosed in Notes 1 and 6, respectively, to our accompanying Condensed Consolidated Financial Statements.

### Long-Term Debt

At June 30, 2023, using the last 12 months of Adjusted EBITDA, our ratio of total long‑term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 4.14x. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our Credit Agreement as a source of liquidity and acquisitions that involve the assumption of long‑term debt. We seek to manage this ratio and increase the efficiency of our balance sheet by following our business plan and managing our cost structure, including through possible asset divestitures, and through other changes in our capital structure. As part of our long‑term objective to manage our capital structure, we continue to evaluate opportunities to retire, purchase, redeem and refinance outstanding debt subject to prevailing market conditions, our liquidity requirements, operating results, contractual restrictions and other factors. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward‑Looking Statements and Risk Factors sections in Part I of our Annual Report.

Interest payments, net of capitalized interest, were $445 million and $416 million in the six months ended June 30, 2023 and 2022, respectively.

### Share Repurchase Program

In October 2022, our board of directors authorized a $1 billion share repurchase program. The timing and amounts of repurchases will be based on management’s discretion, subject to market conditions and other factors. The share repurchase program does not obligate us to acquire any particular amount of common stock, and it may be suspended for periods or discontinued at any time before its scheduled expiration.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $196 million of standby letters of credit outstanding and guarantees at June 30, 2023.

### Other Cash Requirements

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), surgical hospital expansion focused on higher acuity services, equipment and information systems additions and replacements, introduction of new medical technologies (including robotics), design and construction of new facilities, and various other capital improvements. We continue to implement our portfolio diversification strategy into ambulatory surgery and have a baseline intention to invest $250 million annually in ambulatory business acquisitions and de novo facilities. Capital expenditures were $367 million and $307 million in the six months ended June 30, 2023 and 2022, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, 2023 will total approximately $675 million to $725 million, including $196 million that was accrued as a liability at December 31, 2022.

We made income tax payments, net of tax refunds, of $158 million during the six months ended June 30, 2023 compared to $140 million during the same period in 2022.

### SOURCES AND USES OF CASH

Our liquidity for the six months ended June 30, 2023 was primarily derived from net cash provided by operating activities and cash on hand. We had $934 million of cash and cash equivalents on hand at June 30, 2023 to fund our operations and capital expenditures, and our borrowing availability under our Credit Agreement was $1.500 billion based on our borrowing base calculation at June 30, 2023.

Our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions, due to shifts in payer mix and other factors. Our Credit Agreement provides additional liquidity to manage fluctuations in operating cash caused by these factors.

Net cash provided by operating activities was $1.047 billion in the six months ended June 30, 2023 compared to $347 million in the six months ended June 30, 2022. Key factors contributing to the change between the 2023 and 2022 periods included the following:

- No Medicare advances recouped or repaid in the six months ended June 30, 2023 compared to $475 million recouped or repaid during the same period in 2022;
- Higher interest payments of $29 million during the six months ended June 30, 2023 compared to the same period in 2022;
- Higher income tax payments of $18 million in the 2023 period; and
- The timing of other working capital items.

Net cash used in investing activities was $467 million for the six months ended June 30, 2023 compared to $200 million for the six months ended June 30, 2022. Proceeds from sales of facilities and other assets were $193 million lower during the 2023 period, primarily due to the sale of the several medical office buildings in the six months ended June 30, 2022. Additionally, capital expenditures increased by $60 million in the six months ended June 30, 2023 compared to the same period in 2022.

We used net cash of $504 million and $1.160 billion for financing activities in the six months ended June 30, 2023 and 2022, respectively. The 2023 period included proceeds from the issuance of $1.350 billion aggregate principal amount of our 2031 Senior Secured First Lien Notes, which proceeds were subsequently used, together with cash on hand, to finance the redemption of the combined $1.345 billion aggregate principal amount outstanding of our September 2024 Senior Secured First Lien Notes and July 2024 Senior Secured First Lien Notes. In addition, financing activities during the six‑month period in 2023 included distributions of $270 million to noncontrolling interest holders, payments totaling $90 million to repurchase 1,485,983 shares of our common stock and payments of $79 million to purchase noncontrolling ownership interests.

Financing activities during the six months ended June 30, 2022 included long-term debt payments of $2.744 billion, including $1.933 billion paid to redeem all $1.872 billion aggregate principal amount outstanding of our 6.750% senior unsecured notes due 2023 and $730 million paid to redeem all $700 million aggregate principal amount outstanding of our 7.500% senior secured first lien notes due 2025. In addition, we paid distributions of $310 million to noncontrolling interest holders during the six‑month period in 2022, which included the distribution of $61 million for minority interest holders’ portion of the proceeds received from the sale of several medical office buildings. These payments were partially offset by proceeds of $2.000 billion from the issuance of our 6.125% senior secured first lien notes due 2030 during the six months ended June 30, 2022.

We record our equity securities and our debt securities classified as available‑for‑sale at fair market value. The majority of our investments are valued based on quoted market prices or other observable inputs. We have no investments that we expect will be negatively affected by the current economic conditions and materially impact our financial condition, results of operations or cash flows.

### DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS

*Credit Agreement—*At June 30, 2023, our Credit Agreement provided for revolving loans in an aggregate principal amount of up to $1.500 billion with a $200 million subfacility for standby letters of credit. At June 30, 2023, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.500 billion was available for borrowing under the Credit Agreement at June 30, 2023. We were in compliance with all covenants and conditions in our Credit Agreement at June 30, 2023.

*Letter of Credit Facility—*We have a letter of credit facility (as amended to date, the “LC Facility”) that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200 million. The scheduled maturity date of the LC Facility is September 12, 2024. The LC Facility is subject to an effective maximum secured debt covenant of 4.25 to 1.00. At June 30, 2023, we were in compliance with all covenants and conditions in the LC Facility, and we had $111 million of standby letters of credit outstanding thereunder.

*Senior Unsecured Notes and Senior Secured Notes—*At June 30, 2023, we had outstanding senior unsecured notes and senior secured notes with aggregate principal amounts outstanding of $14.762 billion. These notes have fixed interest rates and require semi-annual interest payments in arrears. The principal and any accrued but unpaid interest is due upon the maturity date of the respective notes, which dates are staggered from January 2026 through November 2031.

In May 2023, we issued $1.350 billion aggregate principal amount of our 2031 Senior Secured First Lien Notes. We will pay interest on these notes semi-annually in arrears on May 15 and November 15 of each year, commencing on November 15, 2023. We used the issuance proceeds, together with cash on hand, to finance the redemption of the entire aggregate principal amounts outstanding of our September 2024 Senior Secured First Lien Notes and our July 2024 Senior Secured First Lien Notes in the three months ended June 30, 2023.

For additional information regarding our long-term debt, see Note 6 to the accompanying Condensed Consolidated Financial Statements and Note 8 to the Consolidated Financial Statements included in our Annual Report.

### LIQUIDITY

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day‑to‑day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest payments and income tax payments. These fluctuations can result in material intra-quarter net operating and investing uses of cash that have caused, and in the future may cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, borrowing availability under our Credit Agreement and anticipated future cash provided by our operating activities should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to current and former joint venture partners, including those related to our share purchase agreement with Baylor, and other presently known operating needs.

Various aspects of our operations continue to experience adverse impacts of the COVID‑19 pandemic, although to a much lesser extent than previously experienced. If new variants emerge and cause surges in COVID‑19 cases, the local economies of areas we serve could be negatively affected. Any significant deterioration in the collectability of patient accounts receivable could adversely affect our cash flows and results of operations. If general economic conditions deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be impacted.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual or regulatory commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate sufficient cash from operations, as well as by the various risks and uncertainties discussed in this section, other sections of this report and in our Annual Report, including any costs associated with legal proceedings and government investigations.

We have not relied on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our balance sheet. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest except for borrowings, if any, under our Credit Agreement.

### CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions. Our critical accounting estimates have not changed from the description provided in our Annual Report.

## Market risk

As filed, 1,313 characters.

The following table presents information about certain of our market-sensitive financial instruments at June 30, 2023. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the end of the reporting period. The effects of unamortized discounts and issue costs are excluded from the table.

*(Dollars in Millions)*

|  | Maturity Date, Years Ending December 31, 2023 | 2024 | 2025 | 2026 | 2027 | Thereafter | Total | Fair Value |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Fixed rate long-term debt | $81 | $123 | $89 | $2,143 | $3,022 | $9,721 | $15,179 | $14,566 |
| Average effective interest rates | 6.2% | 6.2% | 7.1% | 4.9% | 5.7% | 5.6% | 5.6% |  |

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities. We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

## Controls and procedures

As filed, 1,079 characters.

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective as of June 30, 2023 to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 137 characters.

There have been no material changes to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022.

Filed Jul 31, 2023.
Source: SEC EDGAR, the filing index for accession 0000070318-23-000041. Last ingested by Listed: Nov 15, 2026, 02:42 ET. No prices; not investment advice.
